Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Methylphenidate shows early promise in vascular cognitive impairment

Jackey Suen
26 Nov 2018
Dr Jolien Leijenaar

Methylphenidate was found to improve executive functioning in patients with vascular cognitive impairment (VCI) in the STREAM-VCI study.

“Executive dysfunction and memory impairment are the most common symptoms in patients with VCI,” noted investigator Dr Jolien Leijenaar of the Amsterdam University Medical Center, the Netherlands. “Executive functioning is modulated by the monoaminergic neurotransmitter system, while memory is modulated by the cholinergic neurotransmitter system. Drugs that can modulate these two systems may therefore represent potential treatment options for VCI symptoms.”

STREAM-VCI is a proof-of-concept, single-centre, double-blind study that investigated the efficacy of methylphenidate, a monoaminergic neurotransmitter, and galantamine, a cholinergic neurotransmitter, in 30 patients with VCI. The patients received treatment with methylphenidate 10 mg, galantamine 16 mg and placebo in a randomized sequence in three follow-up visits.

Results showed significant improvement in executive functioning after methylphenidate administration (p=0.0021 vs galantamine; p=0.0016 vs placebo).

“No serious adverse events [AEs] occurred in any of the patients,” reported Leijenaar. “More patients experienced blood pressure increase, dizziness, nausea, vomiting, fatigue, diarrhoea and hyperhidrosis after administration of galantamine. Methylphenidate’s AE profile was generally comparable to that of placebo, except for a higher incidence of hypervigilance [14 percent vs 0 percent].”

“We also found that patients’ performance in delayed word recall worsened after the administration of galantamine, which may be due to AEs,” noted Leijenaar.

“Our next step is to correlate the response to methylphenidate and galantamine with structural and functional MRI,” she added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.